Two Sigma Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-34,844
| Closed | -$38K | – | 2583 |
|
|
2023
Q3 | $38K | Buy |
+34,844
| New | +$38K | ﹤0.01% | 2297 |
|
|
2021
Q3 | – | Sell |
-359,316
| Closed | -$1.65M | – | 2583 |
|
|
2021
Q2 | $1.65M | Buy |
359,316
+294,743
| +456% | +$1.35M | ﹤0.01% | 1393 |
|
|
2021
Q1 | $379K | Buy |
+64,573
| New | +$379K | ﹤0.01% | 2127 |
|
|
2020
Q3 | – | Sell |
-455,816
| Closed | -$909K | – | 2542 |
|
|
2020
Q2 | $909K | Buy |
455,816
+17,900
| +4% | +$35.7K | ﹤0.01% | 1619 |
|
|
2020
Q1 | $854K | Buy |
437,916
+148,200
| +51% | +$289K | ﹤0.01% | 1571 |
|
|
2019
Q4 | $1.2M | Buy |
289,716
+226,100
| +355% | +$938K | ﹤0.01% | 1488 |
|
|
2019
Q3 | $191K | Buy |
63,616
+36,600
| +135% | +$110K | ﹤0.01% | 2051 |
|
|
2019
Q2 | $170K | Sell |
27,016
-9,900
| -27% | -$62.3K | ﹤0.01% | 2159 |
|
|
2019
Q1 | $205K | Buy |
36,916
+8,500
| +30% | +$47.2K | ﹤0.01% | 2106 |
|
|
2018
Q4 | $189K | Buy |
28,416
+12,739
| +81% | +$84.7K | ﹤0.01% | 2144 |
|
|
2018
Q3 | $167K | Sell |
15,677
-18,200
| -54% | -$194K | ﹤0.01% | 2108 |
|
|
2018
Q2 | $407K | Buy |
33,877
+19,229
| +131% | +$231K | ﹤0.01% | 1998 |
|
|
2018
Q1 | $126K | Buy |
14,648
+4,072
| +39% | +$35K | ﹤0.01% | 2206 |
|
|
2017
Q4 | $104K | Buy |
+10,576
| New | +$104K | ﹤0.01% | 2146 |
|
|
2017
Q2 | – | Sell |
-25,105
| Closed | -$360K | – | 2328 |
|
|
2017
Q1 | $360K | Sell |
25,105
-43,648
| -63% | -$626K | ﹤0.01% | 2028 |
|
|
2016
Q4 | $951K | Sell |
68,753
-90,750
| -57% | -$1.26M | ﹤0.01% | 1584 |
|
|
2016
Q3 | $2.88M | Buy |
159,503
+143,317
| +885% | +$2.59M | 0.01% | 860 |
|
|
2016
Q2 | $232K | Buy |
+16,186
| New | +$232K | ﹤0.01% | 1814 |
|
|
2015
Q1 | – | Sell |
-21,373
| Closed | -$136K | – | 2044 |
|
|
2014
Q4 | $136K | Buy |
+21,373
| New | +$136K | ﹤0.01% | 1966 |
|